Publication
Title
Adjuvant therapy for resectable pancreatic adenocarcinoma : review of the current treatment approaches and future directions
Author
Abstract
Adenocarcinoma of the pancreas carries a uniformly poor prognosis with high rates of loco-regional as well as systemic recurrence. Outcomes remain poor, even for early stage and resectable disease. It is perceived as inherently resistant to most of the currently available treatment options. Evidence supports the need for adjuvant chemotherapy but controversy remains in relation to the use of combined therapy, novel agents and the most appropriate timing of therapy. Despite no clear consensus, mainstay of treatment following resection is based primarily on single agent gemcitabine. Promising new agents and molecules of prognostic as well as predictive value under evaluation offer intriguing data, despite issues surrounding adjuvant therapy strategies. In this article, we sought to review the different therapeutic adjuvant modalities and future directions. (C) 2013 Elsevier Ltd. All rights reserved.
Language
English
Source (journal)
Cancer treatment reviews. - London
Publication
Oxford : Elsevier sci ltd, 2014
ISSN
0305-7372
Volume/pages
40:1(2014), p. 78-85
ISI
000328871200009
Full text (Publishers DOI)
UAntwerpen
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 17.11.2015
Last edited 10.04.2017
To cite this reference